Skip to main content
SpringerLink
Log in
Book cover

Diagnosis and Management of Autoimmune Hepatitis pp 93–108Cite as

Treating the Adult Patient: Alternative Drug Therapies

  • Chapter
  • First Online:

  • 432 Accesses

Abstract

Standard therapy for autoimmune hepatitis can be limited by drug intolerance or inadequate biochemical response. After optimizing drug doses and excluding noncompliance, alternative immunosuppressive agents need to be considered. This chapter will review the role of second-line agents in the treatment of autoimmune hepatitis.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Czaja AJ. Diagnosis and management of autoimmune hepatitis: current status and future directions. Gut Liver. 2016;10(2):177–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46(4):1138–44.

    Article  CAS  PubMed  Google Scholar 

  3. Manns MP, Czaja AJ, Gordon JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):1–31.

    Article  CAS  Google Scholar 

  4. Lohse AW, Chazouilleres O, Dalekos G, Drenth J, Heneghan M, Hofer H, Lammert F, Lenzi M. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63:971–1004.

    Article  Google Scholar 

  5. Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: standard treatment and systematic review of alternative treatments. World J Gastroenterol. 2017;23(33):6030–48.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Yeoman AD, Westbrook RH, Zen Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology. 2011;53(3):926–34.

    Article  PubMed  Google Scholar 

  7. van Gerven NM, Verwer BJ, Witte BI, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol. 2014;49(10):1245–54.

    Article  PubMed  CAS  Google Scholar 

  8. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther. 1994;8(6):585–90.

    Article  CAS  PubMed  Google Scholar 

  9. Geier A, Gartung C, Dietrich CG, et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: effect of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol. 2003;9(12):2681–5.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198–206.

    Article  CAS  PubMed  Google Scholar 

  11. Peiseler M, Liebscher T, Sebode M, et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2018;16:260–7.

    Article  CAS  PubMed  Google Scholar 

  12. Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology. 1996;110(1):271–4.

    Article  CAS  PubMed  Google Scholar 

  13. Lees CW, Maan AK, Hansoti B, et al. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:220–7.

    Article  CAS  PubMed  Google Scholar 

  14. Hindorf U, Johansson M, Eriksson A, et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:654–61.

    Article  CAS  PubMed  Google Scholar 

  15. http://livertox.nlm.nih.gov.

  16. Hubener S, Oo YH, Than NN, et al. Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance. Clin Gastroenterol Hepatol. 2016;14:445–53.

    Article  PubMed  CAS  Google Scholar 

  17. Legue C, Legros L, Kammerer-Jacquet S, et al. Safety and efficacy of 6-thioguanine as a second-line treatment for autoimmune hepatitis. Clin Gastroenterol Hepatol. 2018;16:290–1.

    Article  CAS  PubMed  Google Scholar 

  18. van den Brand FF, van Nieuwkerk CM, Verwer BJ, et al. Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in the Netherlands. Aliment Pharmacol Ther. 2018;48:761–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. de Boer YS, van Gerven NM, de Boer NK, et al. Allopurinol safely and effectively optimizes thiopurine metabolites in patients with autoimmune hepatitis. Aliment Pharmacol Ther. 2013;37:640–6.

    Article  PubMed  CAS  Google Scholar 

  20. Zachou K, Gatselis N, Papadamou G, et al. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol. 2011;55:636–46.

    Article  CAS  PubMed  Google Scholar 

  21. Wolf DC, Bojito L, Facciuto M, et al. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci. 2009;54(11):2519–22.

    Article  CAS  PubMed  Google Scholar 

  22. Jothimani D, Cramp ME, Cross TJ. Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study. J Clin Exp Hepatol. 2014;4(3):221–5.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther. 2011;34(3):335–43.

    Article  CAS  PubMed  Google Scholar 

  24. Hlivko JT, Shiffman ML, Stravitz RT, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6(9):1036–40.

    Article  CAS  PubMed  Google Scholar 

  25. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol. 2008;103(12):3063–70.

    Article  CAS  PubMed  Google Scholar 

  26. Sharzehi K, Huang MA, Shreibman IR, et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory of intolerant to conventional therapy. Can J Gastroenterol. 2010;24(10):588–92.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Roberts SK, Lim R, Strasser S, et al. Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy. Clin Gastroenterol Hepatol. 2018;16:268–77.

    Article  CAS  PubMed  Google Scholar 

  28. Czaja AJ. Autoimmune hepatitis: focusing on treatments other than steroids. Can J Gastroenterol. 2012;26(9):615–20.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Czaja AJ. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther. 2013;38:343–64.

    Article  CAS  PubMed  Google Scholar 

  30. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001;46(6):1321–7.

    Article  CAS  PubMed  Google Scholar 

  31. Hanouneh M, Ritchie MM, Ascha M, et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis. Scand J Gastroenterol. 2019;54(1):76–80.

    Article  CAS  PubMed  Google Scholar 

  32. Efe C, Hagstrom H, Ytting H, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2017;15:1950–6.

    Article  CAS  PubMed  Google Scholar 

  33. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs. 2007;67(3):369–91.

    Article  CAS  PubMed  Google Scholar 

  34. Kerkar N, Dugan C, Rumbo C, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant. 2005;5(5):1085–9.

    Article  PubMed  Google Scholar 

  35. Chatrath H, Allen L, Boyer TD. Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med. 2014;127(11):1128–31.

    Article  CAS  PubMed  Google Scholar 

  36. Ytting H, Larsen FS. Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. Scand J Gastroenterol. 2015;50(8):1025–31.

    Article  CAS  PubMed  Google Scholar 

  37. Evans JT, Shephard MM, Oates JC, et al. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol. 2008;42(7):862–3.

    Article  PubMed  Google Scholar 

  38. Barth E, Clawson J. A case of autoimmune hepatitis treated with rituximab. Case Rep Gastroenterol. 2010;4(3):502–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Santos ES, Arosemena LR, Raez LE, et al. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int. 2006;26(5):625–9.

    Article  CAS  PubMed  Google Scholar 

  40. Carey EJ, Somaratne K, Rakela J. Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome. Rev Med Chil. 2011;139(11):1484–7.

    Article  PubMed  Google Scholar 

  41. Burak KW, Swain MG, Santodomino-Garzon T, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol. 2013;27(5):273–80.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Perrillo RP, Gish R, Falck-Ytter YT. American gastroenterological association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221–44.

    Article  PubMed  Google Scholar 

  43. Fujii K, Rokutanda R, Osugi Y, et al. Adult-onset Still’s disease complicated by autoimmune hepatitis: successful treatment with infliximab. Intern Med. 2012;51:1125–8.

    Article  CAS  PubMed  Google Scholar 

  44. Vallejo SN, Fernandez CJ, Molina PE, et al. Onset of severe acute autoimmune hepatitis refractory to conventional treatment, rescued with infliximab. Gastroenterol Hepatol. 2014;37(9):524–6.

    Article  Google Scholar 

  45. Weiler-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013;58:529–34.

    Article  CAS  PubMed  Google Scholar 

  46. Borman MA, Urbanski S, Swain MG. Anti-TNF-induced autoimmune hepatitis. J Hepatol. 2014;61:169–70.

    Article  CAS  PubMed  Google Scholar 

  47. Doycheva I, Watt KD, Gulamhusein AF. Autoimmune hepatitis: current and future therapeutic options. Liver Int. 2019;39:1002–13.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hepatology, Carolinas Medical Center-Atrium Health, Charlotte, NC, USA

    Paul A. Schmeltzer

Authors
  1. Paul A. Schmeltzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul A. Schmeltzer .

Editor information

Editors and Affiliations

  1. Carolinas Medical Center-Atrium Health, University of North Carolina School of Medicine, Charlotte, NC, USA

    Mark W. Russo

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Schmeltzer, P.A. (2020). Treating the Adult Patient: Alternative Drug Therapies. In: Russo, M. (eds) Diagnosis and Management of Autoimmune Hepatitis. Springer, Cham. https://doi.org/10.1007/978-3-030-33628-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-33628-8_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-33627-1

  • Online ISBN: 978-3-030-33628-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation